LENVIMA® for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer

Mechanism of action (MOA) of LENVIMA

LENVIMA is thought to block receptors required for tumor growth and blood vessel development1

  • LENVIMA is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor receptors (VEGFR): VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)2
  • LENVIMA inhibits other kinases (including FGFR1, 2, 3, and 4; PDGFRα, KIT, and RET) that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression, in addition to their normal cellular functions2

VEGF=vascular endothelial growth factor; FGF=fibroblast growth factor; VEGFR=vascular endothelial growth factor; FGFR=fibroblast growth factor receptor; FLT=Fms-related tyrosine; KDR=kinase insert domain receptor; PDGFRα =platelet-derived growth factor receptor alpha; RET=rearranged during transfection.